CardiaCare has developed the world's first wearable therapy for treating Atrial Fibrillation. Despite new therapies, Atrial fibrillation (AFib) is still the most common sustained arrhythmia and is considered a rising epidemic affecting millions of people world wide. CardiaCare technology utilizes noninvasive peripheral neuromodulation to mediate a cardiovascular anti arrhythmic response that reduces atrial fibrillation burden. The technology employs a closed loop approach involving both monitoring and therapy. With expert leadership and enthusiastic investors CardiaCare is now planning it’s first regulatory human clinical trial.
